Zeo ScientifiX (Zeo ScientifiX) Float Percentage Of Total Shares Outstanding : 69.65% (As of May. 27, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zeo ScientifiX's float shares is 4.27 Mil. Zeo ScientifiX's total shares outstanding is 6.13 Mil. Zeo ScientifiX's float percentage of total shares outstanding is 69.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zeo ScientifiX's Insider Ownership is 18.56%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zeo ScientifiX's Institutional Ownership is 0.00%.

Zeo ScientifiX Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Zeo ScientifiX's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	4.27	/	6.13
	=	69.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zeo ScientifiX (Zeo ScientifiX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3321 College Avenue, Suite 246, Davie, FL, USA, 33314

Website

https://www.organicell.com

Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.

Executives

Skycrest Holdings, Llc	10 percent owner	1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider	director, officer: CEO and Director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub	officer: Executive Vice President & CSO	23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich	officer: COO and Acting CEO	4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser	director	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn	director	2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz	director	58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi	director	6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh	director	E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste	director
Ryan C Likes	officer: Chief Operating Officer	1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell	10 percent owner, officer: Chief Financial Officer	77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani	director, officer: Chief Executive Officer	4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140